ScAAV9 intracisternal delivery results in efficient gene transfer to the central nervous system of a feline model of motor neuron disease

Human Gene Therapy

Volumn 24, Issue 7, 2013, Pages 670-682

  Bucher, Thomas ^a   Colle, Marie Anne ^b   Wakeling, Erin ^c   Dubreil, Laurence ^b   Fyfe, John ^c   Briot Nivard, Delphine ^a   Maquigneau, Maud ^a   Raoul, Sylvie ^a   Cherel, Yan ^b   Astord, Stéphanie ^d   Duque, Sandra ^d   Marais, Thibaut ^d   Voit, Thomas ^d   Moullier, Philippe ^a,e   Barkats, Martine ^d   Joussemet, Béatrice ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b INRA UMR 703   (France)

^c Michigan State University ^*  (United States)

^d INSERM   (France)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAT; CISTERNA MAGNA; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSDUCTION; MOTOR NEURON DISEASE; NONHUMAN; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ADMINISTRATION, INTRAVENOUS; ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, WESTERN; CATS; CISTERNA MAGNA; DEPENDOVIRUS; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; MOTOR CORTEX; MOTOR NEURON DISEASE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPINAL CORD; TRANSDUCTION, GENETIC; TRANSGENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84880593182     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.218     Document Type: Article

References (63)

1. Azzouz, M., Ralph, G.S., Storkebaum, E., et al. (2004). VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429, 413-417.
2. Bevan, A.K., Duque, S., Foust, K.D., et al. (2011). Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol. Ther. 19, 1971-1980.
3. Borasio, G.D., Robberecht, W., Leigh, P.N., et al. (1998). A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology 51, 583-586.
4. Brockington, A., Wharton, S.B., Fernando, M., et al. (2006). Expression of vascular endothelial growth factor and its receptors in the central nervous system in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 65, 26-36.
5. Ciron, C., Desmaris, N., Colle, M.A., et al. (2006). Gene therapy of the brain in the dog model of Hurler's syndrome. Ann. Neurol. 60, 204-213.
6. Ciron, C., Cressant, A., Roux, F., et al. (2009). AAV1-, AAV2- and AAV5-mediated human alpha-iduronidase gene transfer in the brain of nonhuman primate: vector diffusion and bio distribution. Hum Gene Ther. [Epub ahead of print]
7. Devos, D., Moreau, C., Lassalle, P., et al. (2004). Low levels of the vascular endothelial growth factor in CSF from early ALS patients. Neurology 62, 2127-2129.
8. Dodge, J.C., Haidet, A.M., Yang, W., et al. (2008). Delivery of AAVIGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity. Mol. Ther. 16, 1056-1064.
9. Dominguez, E., Marais, T., Chatauret, N., et al. (2011). Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum. Mol. Genet. 20, 681-693.
10. Duque, S., Joussemet, B., Riviere, C., et al. (2009). Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons. Mol. Ther. 17, 1187-1196.
11. Federici, T., Taub, J.S., Baum, G.R., et al. (2011). Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs. Gene. Ther. 19, 852-859.
12. Ferrara, N., Gerber, H.P., and Lecouter, J. (2003). The biology of VEGF and its receptors. Nat. Med. 9, 669-676.
13. Foust, K.D., Flotte, T.R., Reier, P.J., and Mandel, R.J. (2008). Recombinant adeno-associated virus-mediated global anterograde delivery of glial cell line-derived neurotrophic factor to the spinal cord: comparison of rubrospinal and corticospinal tracts in the rat. Hum. Gene Ther. 19, 71-82.
14. Foust, K.D., Nurre, E., Montgomery, C.L., et al. (2009). Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27, 59-65.
15. Foust, K.D., Wang, X., McGovern, V.L., et al. (2010). Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat. Biotechnol. 28, 271-274.
16. Fu, H., Dirosario, J., Kang, L., et al. (2010). Restoration of central nervous system alpha-N-acetylglucosaminidase activity and therapeutic benefits in mucopolysaccharidosis IIIB mice by a single intracisternal recombinant adeno-associated viral type 2 vector delivery. J. Gene Med. 12, 624-633.
17. Fyfe, J.C., Menotti-Raymond, M., David, V.A., et al. (2006). An approximately 140-kb deletion associated with feline spinal muscular atrophy implies an essential LIX1 function for motor neuron survival. Genome Res. 16, 1084-1090.
18. Giot, L., Bader, J.S., Brouwer, C., et al. (2003). A protein interaction map of Drosophila melanogaster. Science 302, 1727-1736.
19. Glascock, J.J., Osman, E.Y., Wetz, M.J., et al. (2012). Decreasing disease severity in symptomatic, Smn( - / - );SMN2( + / + ), spinal muscular atrophy mice following scAAV9-SMN delivery. Hum. Gene Ther. 23, 330-335.
20. Gozes, Y., Moayeri, M., Wiggins, J.F., and Leppla, S.H. (2006). Anthrax lethal toxin induces ketotifen-sensitive intradermal vascular leakage in certain inbred mice. Infect. Immun. 74, 1266-1272.
21. Gray, S.J., Foti, S.B., Schwartz, J.W., et al. (2011a). Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum. Gene Ther. 22, 1143-1153.
22. Gray, S.J., Matagne, V., Bachaboina, L., et al. (2011b). Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol. Ther. 19, 1058-1069.
23. Greenberg, D.A., and Jin, K. (2005). From angiogenesis to neuropathology. Nature 438, 954-959.
24. He, Q., Lowrie, C., Shelton, G.D., et al. (2005). Inherited motor neuron disease in domestic cats: a model of spinal muscular atrophy. Pediatr. Res. 57, 324-330.
25. Hollis, E.R., 2nd, Kadoya, K., Hirsch, M., et al. (2008). Efficient retrograde neuronal transduction utilizing self-complementary AAV1. Mol. Ther. 16, 296-301.
26. Hua, Y., Sahashi, K., Rigo, F., et al. (2011). Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 478, 123-126.
27. Hutson, T.H., Verhaagen, J., Yanez-Munoz, R.J., and Moon, L.D. (2012). Corticospinal tract transduction: a comparison of seven adeno-associated viral vector serotypes and a non-integrating lentiviral vector. Gene Ther. 19, 49-60.
28. Ito, D., and Suzuki, N. (2011). Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS. Neurology 77, 1636-1643.
29. Ito, Y., Yamamoto, M., Li, M., et al. (1998). Differential temporal expression of mRNAs for ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), interleukin-6 (IL-6), and their receptors (CNTFR alpha, LIFR beta, IL-6R alpha and gp130) in injured peripheral nerves. Brain Res. 793, 321-327.
30. Iwamoto, N., Watanabe, A., Yamamoto, M., et al. (2009). Global diffuse distribution in the brain and efficient gene delivery to the dorsal root ganglia by intrathecal injection of adenoassociated viral vector serotype 1. J. Gene Med. 11, 498-505.
31. Jablonka, S., Rossoll, W., Schrank, B., and Sendtner, M. (2000). The role of SMN in spinal muscular atrophy. J. Neurol. 247 Suppl 1, I37-I42.
32. Kariya, S., Park, G.H., Maeno-Hikichi, Y., et al. (2008). Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum. Mol. Genet. 17, 2552-2569.
33. Kaspar, B.K., Llado, J., Sherkat, N., et al. (2003). Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301, 839-842.
34. Lambrechts, D., Storkebaum, E., Morimoto, M., et al. (2003). VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat. Genet. 34, 383-394.
35. Lauria, G., Campanella, A., Filippini, G., et al. (2009). Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability. Amyotroph. Lateral Scler. 10, 410-415.
36. Lunn, M.R., and Wang, C.H. (2008). Spinal muscular atrophy. Lancet 371, 2120-2133.
37. Mcwhorter, M.L., Monani, U.R., Burghes, A.H., and Beattie, C.E. (2003). Knockdown of the survival motor neuron (Smn) protein in zebrafish causes defects in motor axon outgrowth and pathfinding. J. Cell Biol. 162, 919-931.
38. Miller, R.G., Bryan, W.W., Dietz, M.A., et al. (1996). Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis. Neurology 47, 1329-1331.
39. Murohara, T., Horowitz, J.R., Silver, M., et al. (1998). Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 97, 99-107.
40. Ochs, G., Penn, R.D., York, M., et al. (2000). A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 1, 201-206.
41. Oosthuyse, B., Moons, L., Storkebaum, E., et al. (2001). Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat. Genet. 28, 131-138.
42. Rabinowitz, J.E., Rolling, F., Li, C., et al. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. 76, 791-801.
43. Robinson, S.D., Reynolds, L.E., Wyder, L., et al. (2004). Beta3-integrin regulates vascular endothelial growth factor-Adependent permeability. Arterioscler. Thromb. Vasc. Biol. 24, 2108-2114.
44. Rossoll, W., Jablonka, S., Andreassi, C., et al. (2003). Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motoneurons. J. Cell Biol. 163, 801-812.
45. Salegio, E.A., Samaranch, L., Kells, A.P., et al. (2013). Axonal transport of adeno-associated viral vectors is serotypedependent. Gene Ther. 20, 348-352.
46. Samaranch, L., Salegio, E.A., San Sebastian, W., et al. (2012). Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum. Gene Ther. 23, 382-389.
47. Samaranch, L., Salegio, E.A., San Sebastian, W., et al. (2013). Strong cortical and spinal cord transduction after Aav7 and Aav9 delivery into the cerebrospinal fluid of nonhuman primates. Hum. Gene Ther. 24, 526-532.
48. Sathasivam, S. (2008). VEGF and ALS. Neurosci. Res. 62, 71-77.
49. Shababi, M., Habibi, J., Yang, H.T., et al. (2010). Cardiac defects contribute to the pathology of spinal muscular atrophy models. Hum. Mol. Genet. 19, 4059-4071.
50. Snider, S.R. (1961). A Stereotaxic Atlas of the Cat Brain (The University of Chicago Press, Chicago).
51. Snyder, B.R., Gray, S.J., Quach, E.T., et al. (2011). Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery. Hum. Gene Ther. 22, 1129-1135.
52. Storek, B., Reinhardt, M., Wang, C., et al. (2008). Sensory neuron targeting by self-complementary AAV8 via lumbar puncture for chronic pain. Proc. Natl. Acad. Sci. U. S. A. 105, 1055-1060.
53. Storkebaum, E., Lambrechts, D., Dewerchin, M., et al. (2005). Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat. Neurosci. 8, 85-92.
54. Towne, C., Pertin, M., Beggah, A.T., et al. (2009). Recombinant adeno-associated virus serotype 6 (rAAV2/6)-mediated gene transfer to nociceptive neurons through different routes of delivery. Mol. Pain. 5, 52.
55. Towne, C., Schneider, B.L., Kieran, D., et al. (2010). Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6. Gene Ther. 17, 141-146.
56. Tsai, L.K., Chen, Y.C., Cheng, W.C., Ting, C.H., Dodge, J.C., Hwu, W.L., Cheng, S.H., Passini, M.A. (2012). IGF-1 delivery to CNS attenuates motor neuron cell death but does not improve motor function in type III SMA mice. Neurobiol. Dis. 45, 272-279.
57. Valori, C.F., Ning, K., Wyles, M., et al. (2010). Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci. Transl. Med. 2, 35ra42.
58. Van Blitterswijk, M., and Landers, J.E. (2010). RNA processing pathways in amyotrophic lateral sclerosis. Neurogenetics 11, 275-290.
59. Vite, C.H., Passini, M.A., Haskins, M.E., and Wolfe, J.H. (2003). Adeno-associated virus vector-mediated transduction in the cat brain. Gene Ther. 10, 1874-1881.
60. Vitte, J.M., Davoult, B., Roblot, N., et al. (2004). Deletion of murine Smn exon 7 directed to liver leads to severe defect of liver development associated with iron overload. Am. J. Pathol. 165, 1731-1741.
61. Vulchanova, L., Schuster, D.J., Belur, L.R., et al. (2010). Differential adeno-associated virus mediated gene transfer to sensory neurons following intrathecal delivery by direct lumbar puncture. Mol. Pain 6, 31.
62. Wakeling, E.N., Joussemet, B., Costiou, P., et al. (2011). Failure of lower motor neuron radial outgrowth precedes retrograde degeneration in a feline model of SMA. J. Comp. Neurol. 520, 1737-1750.
63. Wang, Y., Kilic, E., Kilic, U., et al. (2005). VEGF overexpression induces post-ischaemic neuroprotection, but facilitates haemodynamic steal phenomena. Brain 128, 52-63.